Supernus Pharmaceuticals, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 579.77M | 667.24M | 607.52M | 661.82M | 718.95M | 8.6% | |
| Cost of Revenue | (75.06M) | (87.22M) | (83.78M) | (77.91M) | (74.56M) | -4.3% | |
Gross Profit | 504.71M | 580.02M | 523.74M | 583.91M | 644.39M | 10.4% | |
| Operating Expenses | |||||||
| Research & Development | (90.47M) | (74.55M) | (91.59M) | (108.80M) | (106.23M) | -2.4% | |
| Selling, General & Administrative | (304.76M) | (377.22M) | (336.36M) | (335.78M) | (485.56M) | 44.6% | |
| General & Administrative | (105.05M) | (109.43M) | (236.66M) | (247.28M) | (196.91M) | -20.4% | |
| Selling & Marketing | (199.71M) | (267.79M) | (99.70M) | (88.50M) | (288.65M) | 226.2% | |
| Depreciation & Amortization | (32.59M) | (85.54M) | (84.86M) | (80.41M) | (91.56M) | 13.9% | |
Operating Income (EBIT) | 86.03M | 46.12M | -5.27M | 81.67M | -36.86M | -145.1% | |
| Non-Operating Items | |||||||
| Interest Income | 10.57M | 21.69M | 10.45M | 16.20M | 13.25M | -18.2% | |
| Interest Expense | (23.42M) | (7.07M) | (2.42M) | — | — | — | |
| Other Income/Expenses (Net) | -12.85M | 14.62M | 8.04M | 16.20M | -12.17M | -175.1% | |
Income Before Tax | 73.17M | 60.74M | 2.77M | 97.87M | -49.03M | -150.1% | |
| Income Tax Expense | (19.75M) | (32.00K) | (1.45M) | (24.00M) | (10.48M) | -143.7% | |
Net Income | 53.42M | 60.71M | 1.32M | 73.86M | -38.55M | -152.2% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $1 | $1 | $0 | $1 | $-1 | -150.7% | |
| Weighted Avg Shares Outstanding | 53.10M | 53.67M | 54.54M | 55.10M | 56.45M | 2.5% | |
| Weighted Avg Shares Outstanding (Diluted) | 54.36M | 61.68M | 55.51M | 55.96M | 56.45M | 0.9% | |
EBITDA | 129.19M | 153.36M | 90.04M | 178.28M | 42.53M | -76.1% |
Explore SUPN
SUPN in the Healthcare
Mid Cap